Astra to Seek U.S. Vaccine Clearance After Missing Target (2)

April 30, 2021, 1:02 PM

AstraZeneca Plc remains committed to getting U.S. emergency clearance for its coronavirus vaccine whose public acceptance has been undercut by a series of missteps and potentially serious rare side effects.

The U.K. drugmaker, which has pledged not to profit from its Covid shot during the pandemic, said it’s still seeking an emergency use authorization in the first half of 2021 and working with U.S. officials on the filing. Astra had said earlier that it would apply for the authorization by mid-April.

The vaccine, developed with the University of Oxford, sold $275 million in the first quarter, Astra reported Friday,...

To read the full article log in.

Learn more about a Bloomberg Law subscription.